Clinical trials
Solid Tumor clinical trials
Below are recruiting solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,667 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07349160RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy called Meta10-TIL, where immune cells from your tumor are modified and given back to you to help fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
BeijingAges 19–70 - NCT06443489RecruitingPhase 1
SHR-4849 for advanced solid tumors
This trial tests a new drug called SHR-4849 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have limited choices.
Jilin City, ChangchunAges 18–75 - NCT07339176RecruitingPhase 1/Phase 2
A trial of N17350 injected into tumors for advanced solid cancers
This trial tests an experimental drug, N17350, that is injected directly into tumors. It is for people with advanced solid tumors that have stopped responding to standard treatments or who cannot receive them. The study aims to see if this approach is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07328217RecruitingPhase 1/Phase 2
Study of GW5282 for advanced solid tumors
This trial tests a new oral drug, GW5282, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this drug can shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05142423RecruitingPhase 1/Phase 2
First study of AK109 plus AK104 for advanced solid cancers
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
Hangzhou, ZhejiangAges 18–75 - NCT07310134RecruitingPhase 1
Study of ZX-8177 for advanced solid tumors
This trial tests a new oral drug (ZX-8177) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with standard options. The goal is to see if it is safe and helps control the disease.
ShanghaiAges 18 years+ - NCT07298772RecruitingPhase 1/Phase 2
Testing SHR-4375 with other therapies for solid tumors
This study tests a new drug called SHR-4375 combined with other cancer treatments for people with advanced solid tumors that haven't gotten better with standard care. The goal is to see if the combination is safe and works against the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07304128RecruitingPhase 1
PLB-002 for advanced solid tumors study
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07274813RecruitingEarly Phase 1
Study of HLX37 for advanced solid tumors that haven't responded to treatment
This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.
ShanghaiAges 18–75 - NCT07275073RecruitingPhase 1
JMT106 for advanced solid tumors
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
ZhejiangAges 18 years+ - NCT07259889RecruitingPhase 1
CEL001 injection safety study for advanced solid tumors
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
BeijingAges 18 years+ - NCT07266285RecruitingPhase 1
Testing BTM-3566 for advanced solid tumors
This trial tests a new drug, BTM-3566, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Houston, TexasAges 18 years+ - NCT07266428RecruitingPhase 1/Phase 2
Study of a new drug (OTP-01) for advanced solid tumors
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT07260591RecruitingPhase 1
VSV-02 for advanced solid tumors that need new options
This trial tests an experimental virus therapy called VSV-02 for people with advanced solid tumors that have not responded to standard treatments. The treatment is given directly into a tumor, aiming to attack cancer from the inside.
Xinxiang, HenanAges 18 years+ - NCT07264803RecruitingPhase 2
Tumor testing to guide treatment for advanced cancers
This trial uses a patient's own tumor tissue to test which drugs might work best for cancers that have returned or not responded to previous treatments. It focuses on advanced gastric cancer and other solid tumors.
Jinan, ShandongAges 18–75 - NCT07256756RecruitingPhase 1
A study of GC203 TIL for advanced solid tumors
This trial tests a new treatment called GC203 TIL, which uses your own immune cells to fight advanced solid tumors. It's for people who have tried standard treatments and have a tumor that can be removed to create this therapy.
ShenzhenAges 18–75 - NCT07251166RecruitingPhase 1
Safety study of GenSci140 for advanced solid tumors
This trial tests a new drug, GenSci140, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
Shenyang, LiaoningAges 18–75 - NCT07252414RecruitingPhase 1
Study of GenSci143 for advanced solid tumors
This trial tests a new drug, GenSci143, for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has spread or come back and you have no other standard options left.
Zhengzhou, HenanAges 18 years+ - NCT07256782RecruitingPhase 1/Phase 2
A study of QLC5508 combinations for advanced solid tumors
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
ShanghaiAges 18 years+ - NCT07241936RecruitingPhase 1/Phase 2
Sirolimus plus ADC drugs for advanced solid tumors
This trial tests a new type of sirolimus (a targeted therapy) combined with antibody-drug conjugates (ADCs) for advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
ShanghaiAges 18–75 - NCT06904131Recruiting
CAR-T cell therapy for advanced gynecological cancers
This trial tests a new type of immunotherapy called CAR-T cells for advanced ovarian, uterine, or other gynecological cancers that have not responded to standard treatments. The CAR-T cells are specially designed to target proteins (MUC1, MSLN, PD-L1) found on cancer cells.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07230977RecruitingPhase 1
GenSci139 for advanced solid tumors
This Phase 1 trial tests an experimental drug called GenSci139 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Jinan, ShandongAges 18 years+ - NCT07229612RecruitingPhase 1/Phase 2
Study of SHR-4298 for advanced solid tumors
This study tests a new drug called SHR-4298 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07229313RecruitingPhase 1
Testing KIVU-107 in advanced solid tumors
This trial tests a new drug, KIVU-107, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this drug is safe and helps shrink or control the cancer.
Santa Monica, CaliforniaAges 18 years+
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor?
- Yes. Clin2 currently lists 1,667 recruiting solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.